Abstract
Outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the pre-imatinib era were poor, particularly if patients did not receive an allogeneic hematopoietic stem cell transplant. This led to the recommendation that all patients with Ph+ ALL, if they were transplant candidates, should be transplanted. With the introduction of imatinib and subsequently other tyrosine kinase inhibitors, patient outcomes improved dramatically, raising the question of whether transplant in first complete molecular remission for these patients is really necessary. This review looks at evidence from clinical studies around the world in an attempt to answer this question.
Original language | English (US) |
---|---|
Pages (from-to) | 345-350 |
Number of pages | 6 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 29 |
Issue number | 4 |
DOIs | |
State | Published - Dec 1 2016 |
Keywords
- ALL
- Acute lymphoblastic leukemia
- Allogeneic
- Cytogenetics
- Dasatinib
- Imatinib
- MRD
- Minimal residual disease
- Nilotinib
- Ph+
- Philadelphia chromosome positive
- Ponatinib
- Stem cell transplant
- TKI
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry